Please assess the completion status of the following clinical trial:

Trial Title: Neurobiology of Sleep and Sleep Treatment Response in Returning Veterans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* OIF/OEF veteran~* Between the ages of 18 and 50 years old~* Not taking medications known to affect sleep or wake function for 2 weeks~Additional selection criteria for PTSD subjects are:~* Trauma occurred three months or more before study entry~* Meeting diagnostic criteria for current PTSD according to the Clinician Administered PTSD Scale (CAPS)~* Participants will remain in ongoing counseling services~Additional selection criterion for non-PTSD healthy subjects:~* Not meet DSM-IV diagnostic criteria for current PTSD~* Have a total score \< 13 on the Beck Depression Inventory~* Participants who are active-duty military personnel will be required to obtain permission from their commander to participate in this study.~Exclusion Criteria:~* Current diagnosis of untreated, severe depression as determined by the Structured Clinical Interview for Diagnostic and Statistical Manual- IV Edition (DSM-IV), non-patient version~* Beck Depression Inventory \> 30~* History of psychotic or bipolar disorder~* Current history (within 3 months) of substance or alcohol abuse~* Significant or unstable acute or chronic medical conditions~* Other current sleep disorders~* Presence of implanted devices or metal in body such as cardiac pacemaker, aneurysm clip, ear implant, shrapnel, neurostimulators or other metal devices~* Fear of closed spaces~* Previous radiation exposure (past year) that exceeds recommended safety limits~* Pregnancy or breast feeding~* Resting blood pressure \< 90/60 at the screening physical examination~* Heart rate \> 100 beats/minutes~* Current use of a beta-blocker~* Use of an alpha-1 antagonist agent in the previous 3 weeks~* Refusal to follow the safety measures in the case of use of a phosphodiesterase 5 inhibitor (Cialis, Viagra, Levitra)~* Unexpected, untreated, or serious EKG findings

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Prazosin (Type: EXPERIMENTAL): Active medication arm. Prazosin is an FDA approved medication, originally designed as an anti-hypertension medication. Side effects of the medication in some include sleepiness and once asleep, sustained sleep.
- Placebo (Type: PLACEBO_COMPARATOR): A placebo is a sugar pill, which will be used to compare with the results of the active medication

Based on this trial design, predict the completion outcome and termination type (if applicable).